Watermark Medical (ARES™)
Apnea Risk Evaluation System,
home sleep test device:

The Watermark Medical™ Apnea Risk Evaluation System (ARES™) integrates physiological data acquired in-home with clinical history and anthropomorphic data to determine the presence and severity of Obstructive Sleep Apnea (OSA). ARES™ has been cleared for use by the United States Food and Drug Administration (FDA), and is ISO 13485 certified for Europe and Canada.

The Watermark Medical ARES Home Sleep test Device integrates:

WM ARES™ Unicorder:

A sleep-wearable, wireless physiological recorder worn on the forehead that acquires and stores up to 3 nights of nocturnal data. WM ARES™ Unicorder measures blood oxygen saturation (SpO2) and pulse rate (reflectance pulse oximetry), airflow (by nasal cannula connected to a pressure transducer), respiratory effort (a combined signal using pressure transducer sensing forehead venous pressure, venous volume by photoplethysmography, and actigraphy), snoring levels (calibrated acoustic microphone), head movement and head position (accelerometers). When worn in the home, the ARES™ provides a better profile of the patient's breathing during sleep in his/her normal environment. Audio and visual indicators notify the user when the ARES™ requires adjustment, thus increasing reliability of the device in the home. The small size of ARES™ allows it to be comfortably worn in all sleep positions.

WM ARES Screener:

A validated predictor of OSA risk (those in need of a sleep study based on a predicted apnea/hypopnea index > 5 events/hour) and OSA severity (i.e., minimal, mild, moderate or severe) using responses to questions about body type, symptoms of daytime drowsiness, snoring, and other sleep-related characteristics or health conditions associated with OSA. The results can be used to rapidly screen large populations to determine a prior probability of obstructive sleep apnea (OSA). The results are also used to supplement the physiological data obtained in the ARES Sleep Apnea Study.